Skip to content

This Site is Intended for Healthcare Professionals Only

Search AI Powered

Latest Stories

PSNC urges pharmacy teams to take part in 2022 Advice Audit

The Pharmaceutical Services Negotiating Committee (PSNC) has urged community pharmacy teams to participate in the 2022 Pharmacy Advice Audit this week.

The audit aims to gather critical evidence and information for use in funding discussions with the government and the NHS and help to make the case for the sector.


“For maximum impact, we need as many pharmacies as possible to take part,” PSNC stated.

To successfully complete the audit, pharmacy teams will need to:

  • Record patient/customer interactions where advice was given by either a non-pharmacist team member and/or a pharmacist.
  • Carry this out for at least one day, recording all consultations.
  • Estimate the percentage of consultations that were recorded during that time period.
  • Rate confidence in the advice given to help identify areas for improvement.
  • Enter the data on PharmOutcomes.

Thanking pharmacy teams who have already taken part in the audit, Mike Dent, PSNC director of Pharmacy Funding, said: “If your pharmacy has not yet taken part – please do consider this if you can. The evidence provided by these audits is critical in helping us to make the case for the sector, and that has never been truer than this year, as we push for government to fund pharmacies for the support they give to ‘walk-in’ patients.”

More For You

Over four million flu vaccines across England in the 2024/25 winter flu season.

Over four million flu vaccines across England in the 2024/25 winter flu season.

CCA release

Community pharmacy administered over four million flu vaccines

Community pharmacy administered over four million flu vaccines across England in the 2024/25 winter flu season, the highest outside of the pandemic, according to the Company Chemists’ Association.

This is nearly 10 per cent higher than the number of flu vaccines administered in 2023/24.

Keep ReadingShow less
Chemotherapy-free leukaemia treatment

The trial found that a combination of two cancer drugs, ibrutinib and venetoclax, could perform better than chemotherapy among patients with chronic lymphocytic leukaemia.

iStock

Chemotherapy-free leukaemia treatment shows promise during trial

In a breakthrough in leukaemia research, scientists in the UK have tested a chemotherapy-free approach, involving a combination of targeted drugs, which may offer better outcomes.

The new treatment could radically change the way chronic lymphocytic leukaemia (CLL), the most common form of leukaemia in adults, is treated.

Keep ReadingShow less
Wales ranked worst for second-trimester abortion access in the UK

Each year about 175 women travel from Wales to England for care

Wales ranked worst for second-trimester abortion access in the UK

A leading healthcare charity has revealed that Wales is the worst part of the United Kingdom for allowing surgical abortions for women.

Surgical abortion is the process removing pregnancy from the womb by inducing local anaesthesia, conscious sedation or general anaesthesia.

Keep ReadingShow less
The fund offers £150 per eligible child - for up to three children per household.

The fund offers £150 per eligible child - for up to three children per household.

Charity reopens funding to ease back to school financial pressures for community pharmacists

Community pharmacists struggling with the costs of their children going back to school can apply for funding from The Leverhulme Trade Charities Trust (LTCT)

The Trust is providing up to £100,000 of support to those working in a community pharmacy or are a registered pharmacist or pharmacy technician

Keep ReadingShow less
Germany's BioNTech to buy CureVac to boost cancer research

Both biotech companies have been working for years in the area of mRNA vaccines and treatments

Germany's BioNTech to buy CureVac to boost cancer research

Germany's BioNTech is buying domestic rival CureVac for $1.25 billion, bringing together two pharmaceutical firms specialised in mRNA technology with the goal of advancing cancer treatments.

BioNTech, which developed the first coronavirus vaccine to be approved in the West along with US pharmaceutical giant Pfizer, said the acquisition would "bring together complementary capabilities and leverage technologies".

Keep ReadingShow less